The Lachman Blog

29
Sep

Fran Zipp to Participate in Women in Leadership Forum at CPhI festival of pharma

After 30 years of being a major global pharmaceutical event uniting buyers and suppliers of fine pharmaceutical chemicals, CPhI in 2020 is moving to a virtual event. This year, CPhI festival of pharma will be held October 5-16, 2020. Fran Zipp, CEO and President, Lachman Consultants, will be participating in the Women in Leadership Forum, being held on Tuesday […]

Read More
29
Sep

Virtual Inspections Bringing Needed Expertise Remotely

Since the start of the pandemic when travel was limited, Lachman Consultants has been performing inspections.  In fact, we have performed audits and inspections at the same rate as we did before the pandemic, only now, most of them are remote.  We have been at the forefront of implementing effective state-of-the-art solutions.  During this time, […]

Read More
29
Sep

AAM Releases Its 2020 Savings Report

The Association for Accessible Medicines released its 2020 Generic Drugs and Biosimilars Access and Savings in the U.S. Report (here) yesterday, outlining the savings that these products brought to American consumers in 2019. “In 2019, according to data provided by IQVIA, U.S. savings from generic drugs added up to $313 billion—including $96 billion and $48.5 […]

Read More
28
Sep
Youth League Batter

Watch the Inventory of CRLs in Your Court – Don’t be Blindsided, Be Mindful

Did you ever wonder about the FDA’s requirement than an applicant respond to a complete response letter (CRL) within one year of its issuance as provided for in the regulations at 21 CFR 314.110?  Under this regulation, “an applicant must (1) resubmit its ANDA (i.e., submit all materials needed to fully address all deficiencies identified […]

Read More
24
Sep

Benzodiazepine Boxed Warning Update, a Harbinger of Things to Come?

In a drug safety communication on September 23, 2020 titled FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class (here), the FDA announced changes being made to the boxed warning on all benzodiazepine products.  The communication describes the need for the change as follows: “[T]o address the serious risks of abuse, […]

Read More
21
Sep

FDA’s “Be Safe” Program Provides Advice on Online Pharmacies

The news is rife with stories about counterfeit drugs, illegal operating on-line pharmacies, on-line pharmacies dispensing sub- or super-potent medicines, some act as virtual opioid pill mills, but the FDA has launched a campaign to help consumers navigate the online pharmacy morass.  Released this morning the FDA’s web page (here) asks in its opening line […]

Read More
17
Sep
Surprised employer holding long resume, amazed with impressive career achievements

Official August 2020 Approvals and Receipts for ANDAs Reported

The Office of Generic Drugs (OGD) reported some of its official statistics for August today.  As usual, the first official reported metrics deal with approval and tentative approval actions, receipt of new ANDAs, and issuance of complete response letters. The OGD reported 58 full-approval actions (which we nailed in our earlier post of unofficial stats […]

Read More
16
Sep

Weight Loss Drug Voluntarily Withdrawn for Apparent Safety Reasons

The Food and Drug Administration (FDA) is taking final official action withdrawing the approval of two new drug applications for BELVIQ (lorcaserin hydrochloride (HCl)) tablets and BELVIQ XR (lorcaserin HCl) extended-release tablets which were originally approved by FDA on June 27, 2012 and July 15, 2016, respectively.  This announcement was made on the Federal Register’s […]

Read More
14
Sep

Current Coronavirus Factoids

The FDA has been more than busy in its efforts to address the COVID-19 pandemic.  Here is an update as of September 11, 2020 regarding some of the statistics the FDA has presented. The FDA has: Authorized 247 tests under emergency use authorizations (EUAs), of these: 197 are molecular tests 46 are antibody tests 4 […]

Read More
1 2 136